Literature DB >> 32095856

Older Age Significantly Affects Mortality of Patients with Papillary Thyroid Carcinoma Only When They Have High-Risk Features.

Yasuhiro Ito1, Akira Miyauchi2, Takuya Higashiyama2, Hiroo Masuoka2, Minoru Kihara2, Akihiro Miya2.   

Abstract

BACKGROUND: Old age is a known prognostic factor for mortality in patients with papillary thyroid carcinoma (PTC). This study aimed to investigate the relationship between cause-specific survival (CSS) following PTC and the extent of old age.
METHODS: We enrolled 4692 patients aged ≥ 55 years with PTC who underwent surgery between 1989 and 2009 at Kuma Hospital (median follow-up period 140 months). The presence of at least one of the following was used to classify the patients as high risk: (1) tumor sizes > 4 cm, (2) node metastasis ≥ 3 cm, (3) significant extrathyroid extension corresponding to T4a, (4) extranodal tumor extension, and (5) distant metastasis. T1N0M0 PTC was classified as low risk, and all other patients were classified as intermediate risk. We divided all patients into three categories based on age: 55-64, 65-74, and ≥ 75 years.
RESULTS: One low-risk patient (0.04%), 18 intermediate-risk patients (1.5%), and 105 high-risk patients (9.4%) died of PTC, and CSS of high-risk patients was poorer than that of others (p < 0.0001). The CSS of low and intermediate-risk patients did not differ with age. However, CSS of high-risk patients became significantly poorer with advancing age (p = 0.0017 for 55-64 years vs. 65-74 years, and p = 0.0109 for 65-74 years vs. ≥ 75 years).
CONCLUSIONS: Advanced age has a significant prognostic impact on CSS only for high-risk patients with PTC.

Entities:  

Mesh:

Year:  2020        PMID: 32095856     DOI: 10.1007/s00268-020-05429-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  9 in total

1.  Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.

Authors:  Marcia S Brose; Francis P Worden; Kate L Newbold; Matthew Guo; Arti Hurria
Journal:  J Clin Oncol       Date:  2017-06-14       Impact factor: 44.544

2.  Appropriateness of the revised Japanese guidelines' risk classification for the prognosis of papillary thyroid carcinoma: a retrospective analysis of 5,845 papillary thyroid carcinoma patients.

Authors:  Yasuhiro Ito; Akira Miyauchi; Hitomi Oda; Hiroo Masuoka; Takuya Higashiyama; Minoru Kihara; Akihiro Miya
Journal:  Endocr J       Date:  2019-01-09       Impact factor: 2.349

3.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

4.  Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Kiyoshi Ichihara; Hiroo Masuoka; Mitsuhiro Fukushima; Hiroyuki Inoue; Minoru Kihara; Chisato Tomoda; Takuya Higashiyama; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

5.  Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems.

Authors:  Mohamed Abdelgadir Adam; Samantha Thomas; Terry Hyslop; Randall P Scheri; Sanziana A Roman; Julie A Sosa
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

6.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

7.  Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Deborah Kuk; Volkert Wreesmann; Luc Morris; Frank L Palmer; Ian Ganly; Snehal G Patel; Bhuvanesh Singh; R Michael Tuttle; Ashok R Shaha; Mithat Gönen; Jatin P Shah
Journal:  Ann Surg Oncol       Date:  2015-07-28       Impact factor: 5.344

8.  The age factor in survival of a population cohort of well-differentiated thyroid cancer.

Authors:  Andrea Mazurat; Andrea Torroni; Jane Hendrickson-Rebizant; Harbinder Benning; Richard W Nason; K Alok Pathak
Journal:  Endocr Connect       Date:  2013-09-23       Impact factor: 3.335

9.  Prognosis of papillary thyroid carcinoma in elderly patients after thyroid resection: A retrospective cohort analysis.

Authors:  Nathalie Chereau; Christophe Trésallet; Severine Noullet; Gaelle Godiris-Petit; Frederique Tissier; Laurence Leenhardt; Fabrice Menegaux
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  9 in total
  1 in total

1.  Radical neck dissection with advancement flap in advanced papillary thyroid cancer: a therapeutic option.

Authors:  Alex Paul Guachilema Ribadeneira; Cristhian Ramiro García; Andrea Daniela Basantes
Journal:  J Surg Case Rep       Date:  2020-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.